Drug
Opc 64005
Opc 64005: highest development phase Phase 2, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| OPC-64005 NCT03324581 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
Latest
No recent events.
Follow Opc 64005 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.